Before defining a network meta-analysis, Dr. Citrome walks through the statistical fundamentals that make one useful. He ...

Specialty pharmacy workflows—access, education, interaction checks, toxicity management—mitigate BTK antiplatelet risks and ...

Weekly cataplexy rates fell ~79%–89% with oveporexton versus ~28%–39% with placebo, increasing cataplexy-free days from 0 to ~3.8–5.1 weekly. Treatment-emergent adverse events were common (86%–89% vs ...

Drug acquisition costs are trackable, but operational inputs—training time, monitoring intensity, site activation, and ...

The “Washington Ways Without Means” session was moderated by Nick Ferreyros, managing director of policy, advocacy, and ...

Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and ...

Grace Mackleby, PhD, explores why dually eligible beneficiaries more often switch MA plans than leave for traditional ...

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine ...

Dr. Patel defines LEMS as a neuromuscular disorder in which the synapses between nerve and muscle stop firing properly.

The discussion opens with a foundational question: how does limited-stage small cell lung cancer differ from extensive-stage ...

In "Evaluating Suspected LEMS: Differential Diagnosis and Palliative Care's Role," the panel examines how to evaluate a patient once LEMS enters the differential.

Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...